Progress of Castleman disease
10.3760/cma.j.issn.1009-9921.2019.01.006
- VernacularTitle:Castleman病研究进展
- Author:
Hailing LIU
1
;
Lei FAN
Author Information
1. 南京医科大学第一附属医院 江苏省人民医院血液科 210029
- Keywords:
Castleman disease;
Treatment;
Proteomics;
Cytokines
- From:
Journal of Leukemia & Lymphoma
2019;28(1):21-24
- CountryChina
- Language:Chinese
-
Abstract:
Castleman disease (CD) is a rare group of lymphoproliferative disorders with similar clinical manifestations and pathological features to malignant lymphomas. However, due to the extremely low incidence, lack of comparison among large sample clinical cases, laboratory tests, treatment options and prognostic factors, the clinical diagnosis and treatment of CD has encountered great difficulties. The 60th American Society of Hematology (ASH) Annual Meeting has made progresses of CD. In basic research aspects, it mainly explores the relationship of serum proteomics with distinct subtypes and treatment response, gene expression and cell-driven processes of diseases, sources of high cytokine production, and so on. In terms of clinical treatments, personalized treatment based on disease activity status and specific classification provides a new hope for CD patients.
